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Background and methods: Soluble-lymphocyte subsets (sCD19 + CD23+ B cells and sCD4 + CD25+ T cells),
soluble-adhesion molecules (sE-selectin) and interleukin-12 (sIL-12) were assayed to evaluate the pathogenesis of
steroid sensitive nephrotic syndrome in 48 patients diagnosed with steroid sensitive nephrotic syndrome (SSNS) in
active (AS) and remission stages (RS).
Results: The ratios of soluble CD19 and sCD19 + CD23 increased in patients with AS with respect to the patients
with RS and controls (p < 0.05). Increased sCD19 + CD23 ratios were preserved in the patients with RS when
compared with the controls (p < 0.05). Moreover, the ratios of sCD4 + CD25 lymphocyte subsets were not
significantly different among the groups. Similarly, serum sIL-12 levels were not considerably disparate between the
AS and RS. Serum sE-selectin levels were higher in the patients with AS relative to the controls (p < 0.01) and RS
(p < 0.05). No significant correlations were noted between sE-selectin and lymphocyte subset ratios, serum sIL-12
and immunoglobulin levels. There was a positive correlation between sE-selectin, triglyceride (r = 0.757, p < 0.0001)
and cholesterol (r = 0.824, p < 0.0001) levels in patients with the AS.
Conclusion: The present results indicate that the patients with SSNS appear to have abnormalities in sCD23 + CD19
+ cells, defect in T regulatory cell activity, and injury in endothelial cells as indicated by the presence high sE-
selectin. These abnormalities might play a role in the pathogenesis of nephrotic syndrome. sIL-12 seems to have no
role in pathogenesis of nephrotic syndrome reflecting normal Th1 response.
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Interleukin-12Background
Idiopathic nephrotic syndrome (INS) is the most preva-
lent kidney disease in children. Persistent immunogenic
stimuli (such as viral infections, immunizations or aller-
gens) might trigger nephrotic relapses in most of these
patients. A primary immune disturbance is thought to
be responsible for the pathogenesis of nephrotic syn-
drome in childhood. Various studies have attempted to
identify potential abnormalities in lymphocyte subsets
and they reported that during relapses, the subsets of
CD4+ and CD8+ T cells expanded and levels of their
cytokines increased (interleukin-2, IL-4 and interferon-)* Correspondence: bilalyn@yahoo.com
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reproduction in any medium, provided the orin the patients with nephrotic syndrome but reports
regarding these measurements are conflicting [1-4]. Al-
though steroid sensitive idiopathic nephrotic syndrome
is a T lymphocyte mediated disorder, the pathogenetic
role of B lymphocytes, effect of cytokines and vascular
endothelial dysfunctions have not been well established
in nephrotic syndrome. Therefore, in the present study
we aimed to investigate the serum levels of soluble-
lymphocyte subsets (sCD19 + CD23+ B cells and sCD4 +
CD25+ T cells), soluble-adhesion molecule (sE-selectin)
and interleukin-12 (sIL-12) in patients with steroid sensi-
tive nephrotic syndrome (SSNS).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patients and control subjects
We included 48 patients diagnosed with SSNS (32 boys,
16 girls; age range 30–202 months) in the present study.
The control group contained 19 healthy individuals
(12 boys, 7 girls; age range 27–190 months). The pa-
tients were divided into two groups: 28 (58.3%) patients
(20 boys, 8 girls) with active stage (AS) were grouped as
Group 1 at the time of the diagnosis and 20 (41.7%)
patients (12 boys, 8 girls) with remission stage (RS) were
grouped as Group 2. Blood samples were collected before
steroid treatment in Group 1. The patients who did not
response the steroid treatment excluded from the study.
The patients in Group 2 were selected among the steroid
sensitive nephrotic patients at remission stage. The
mean duration of treatment with steroids was 28 weeks
in Group 2. The patients showing complications of
nephrotic syndrome including infection, thrombo-
embolism, osteoporosis or receiving blood transfu-
sions, immunosupresive agents such as cyclosporin
and cyclophosphamide, angiotensin-converting enzyme
inhibitors, non-steroidal anti-inflammatory drugs and
anti-histamines were excluded from the present study.
Active stage was defined as increased urinary protein
excretion >40 mg/m2/h on timed sample or > 3+ by dip-
stick for 3 consecutive days, spot albumin to creatinine
ratio >2 mg/mg and hypoalbuminaemia <2.5 g/dl). Re-
mission stage was defined as urinary protein excretion
<4 mg/m2/h; nil or trace by dipstick on spot sample for
3 consecutive days.
Study protocol
The serum levels of E-selectine and IL-12 + p40 were
measured in the patients with AS before steroid treat-
ment and in RS and in the controls using commercially
available kits (BioSource International, Inc. Camarillo,
California 93012 USA). Assays were performed using
solid phase sandwich ELISA. The blood samples for sE-
selectine, and sIL-12 were kept at −70°C until the time
of assay. Hemoglobin, erythrocyte count, platelet count,
fibrinogen, total protein, cholesterol, triglycerides and
albumin concentration were measured using standard
laboratory methods.
Soluble peripheral lymphocyte subsets (CD3, CD4,
CD8, CD19, sCD19 + CD23+ B cells and sCD4 + CD25+
T cells) were determined using double color flow cytom-
etry (FACScan, Becton Dickinson, Sunnyvale, CA).
Statistical analysis
Data were analyzed using the SPSS for Windows package.
All ranges quoted represent the standard error or devi-
ation. Mann–Whitney U-test, x2 test and Spearman's test
were used for analysis. A p value <0.05 was considered to
be statistically significant.Ethics
The current study was approved by the Research Ethics
Committee of Eskişehir Osmangazi Medical Faculty,
Eskişehir Osmangazi University. Informed consent was
obtained from the parents or guardians of the patients
and control subjects.
Results
Overall, the IgG levels decreased and IgM levels
increased in patients with the AS with regard to the con-
trols and RS. Serum IgE levels also augmented in pa-
tients with the AS with respect to RS the patients and
the controls. Increased levels of IgE were sustained in
the patients with the RS when compared with the con-
trols. The immunoglobulin levels are illustrated in
Table 1.
Subset ratios of the soluble CD3 and CD8 lymphocyte
were similar in all study groups. Subset ratio of the sol-
uble CD4 lymphocyte decreased in patients with the AS
with regard the patients with RS. Moreover, the ratios of
soluble CD19 and sCD19 + CD23 increased as well in
patients with AS in comparison to those with RS and
controls (Table 2). Increased ratios of sCD19 + CD23
were present in patients with RS when compared with
the controls. In addition, sCD4 + CD25 lymphocyte sub-
set ratios were not notably different between the groups
(Table 2). The ratios of lymphocyte subsets are summa-
rized in Table 2.
In addition, serum sIL-12 levels were not considerably
different between the two groups (Table 3, Figure 1).
Serum sE-selectin levels were higher in patients with AS
than controls and RS (Table 3, Figure 1).
No significant correlations were noted between subset
ratios of sE-selectin and lymphocyte, serum sIL-12 and
immunoglobulin levels. There was a positive correlation
between sE-selectin, triglyceride (r = 0.757, p < 0.0001)
and cholesterol (r = 0.824, p < 0.0001) levels in Group 1
(Figure 2A and B).
Discussion
The pathogenesis of INS is currently considered an im-
mune mediated disease with particularly T lymphocyte
involvement. Impairment in the immunoglobulin isotype
switching, which is strongly T lymphocyte-dependent
has been shown [5]. Similar to earlier studies, we mea-
sured markedly decreased IgG levels and considerably
increased IgM levels during AS. However, in the present
study these alterations did not statically persist in the
patients with RS. According to our results, the low IgG
levels might be related B cell disorders. We found low
IgG levels and high CD19 and sCD19 + CD23+ B cell
ratio which reflects increase in number or activity of B
cells (Table 2). These findings suggest a defect in pro-
duction of IgG despite of increased number of B cells.
Table 1 Serum Immunoglobulin (IgA, E, M and G) levels
Relapse (n = 28) (average + SD) Remission (n = 20) (average + SD) Control (n = 19) p
IgA (mg/dl) 93.9 ± 38.8 112.8 ± 70.1 134.5 p1 = NS
p2 = NS
p3 = NS
E (mg/dl) 392.5 ± 193.3 133.4 ± 32.8 32.4 ± 5.6 p1 = 0.01
p2 = 0.001
p3 = 0.019
G (mg/dl) 316.9 ± 237 741.1 ± 288.5 1093 p1 = 0.002
p2 = 0.0001
p3 = NS
M (mg/dl) 200.6 ± 121.9 121 ± 54 125 p1 = 0.002
p2 < 0.05
p3 = NS
p1: relapse vs. remission; p2: relapse vs. controls; p3: remission-controls.
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to be associated with excessive Th2 lymphocyte re-
sponse. According to our findings, dominant T cell
seems to be CD4+ T lymphocytes (Table 2). By contrast,
Lama et al. report an imbalance of the CD4+/ CD8+ T
lymphocytes distribution in favor of CD8+ T lympho-
cytes in relapse and remission in INS [6,7]. The exist-
ence of similar ratio of CD8+ T cells during in AS and
RS and controls in the present study also suggested that
CD8+ T lymphocytes were not dominant lymphocyte inTable 2 The soluble peripheral lymphocyte subsets ratios (%)




CD3 65.8 ± 8.6 71.6 ±
CD4 30.8 ± 6.3 37.4 ±
CD8 27.2 ± 6.3 27.6 ±
CD19 20.3 ± 10.1 13.1 ±
CD19 + CD23 13 ± 9.7 7.7 ± 2
CD4 + CD25 4.8 ± 3.3 3.7 ± 1
p1: relapse vs. remission; p2: relapse vs. controls; p3: remission-controls.patients with nephrotic syndrome. Our present observa-
tion is further supported by another study showing acti-
vation of the NFκB and c-maf transcription factors in
CD4+ T lymphocytes during relapse [8]. Despite of
increased CD4+ T cells, sCD4 + CD25+ T cells were not
increased in our patients with AS. The absence of
increased sCD4 + CD25+ T cells might result in in-
creased Th2 response. In fact, there were increased IgE
levels and similar sIL-12 levels in AS, RS and the con-
trols which showed Th2 cell response in our patients(n = 20)
+ SD)
Control (n = 19)
(average + SD)
p
6.3 69.4 ± 9.5 p1 = NS
p2 = NS
p3 = NS
6.9 35.8 ± 7.4 p1 = 0.019
p2 = NS
p3 = NS
7.1 27.8 ± 6.4 p1 = NS
p2 = NS
p3 = NS
4.2 12.8 ± 6.1 p1 = 0.028
p2 < 0.05
p3 = NS
.9 5.0 ± 2.3 p1 < 0.05
p2 = 0.04
p3 = 0.046
.4 3.6 ± 2.4 p1 = NS
p2 = NS
p3 = NS
Table 3 Serum soluble IL-12 and E-selectin levels
Relapse (n = 28)
(average + SD)
Remission (n = 20)
(average + SD)
Control (n = 19)
(average + SD)
p
Soluble IL-12 277 ± 185.8 172.3 ± 121.3 202.3 ± 45.3 p1 = NS
p2 = NS
p3 = NS
soluble E-selectin 134.8 ± 67,47 88.9 ± 38,8 100.2 ± 37.6 p1 = 0.007
p2 < 0.05
p3 = NS
p1: relapse vs. remission; p2: relapse vs. controls; p3: remission-controls.
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impairment of T regulatory cell (sCD4 + CD25+ T cell)
is present in nephrotic patients.
The B lymphocyte anomalies have not been well stud-
ied so far in children with nephrotic syndrome. Our
study suggests that lymphocyte impairments in neph-
rotic syndrome do not seem to be limited to the T cell.
We found that there were more B lymphocyte expansion
in AS and RS than that of the controls as indicated with
increased sCD19 + CD23+ B lymphocytes and decreased
IgG levels (Table 2). This finding prompted us to think
that reduction of B lymphocytes could be preventing
relapse ratios in patients with nephrotic syndrome. The
therapeutic effects of rituximab, which suppresses B cell
in the peripheral circulation as a chimeric anti-CD20
monoclonal antibody in nephrotic patients, supports our
findings: (i) relapse rates following rituximab treatment
may depend on the recovery of B-cells during the long-
term course [9-11]. (ii) Moreover, rituximab might
increase Treg frequency and number in patients with INS
[12]. We did not find an increase in ratio of sCD4 +
CD25+ T cells in patients with AS. Therefore, the in-
crease of sCD4 +CD25+ Treg cells with rituximab supports
our findings that Treg levels including sCD4 +CD25+ T
cells is not enough in patients with nephrotic syndrome.Figure 1 Serum levels of sIL-12 and sE-selectin. Serum levels of
sIL-12 were similar in patients with active and remission stage and
the controls. Serum E-selectin levels were higher in patients with
active stage than remission satge and the controls.On the other hand, sCD19 + CD23+ B cells are related
to allergic disorders [13]. sCD23 activation mediates IgE
regulation, differentiation of B cells, activation of mono-
cytes, and antigen presentation [14]. We found increased
ratio of sCD19 + CD23+ B cells and serum IgE levels in
AS and RS. These findings suggest that atopy and high
IgE levels might not be related only with Th2 response
in our patients. These findings also suggest that sCD19
+ CD23+ B cells and associated increased serum IgE
could be related to relapse of nephrotic syndrome due to
continued high ratio of sCD19 + CD23+ B cells and IgE
levels in patients with remission.
The sIL-12 is shown to be a master regulator of Th1
response and cell-mediated immunity and sIL-12 can
also up-regulate the production of vascular permeability
factor in INS [15]. Therefore, sIL-12 has been implicated
in the pathogenesis of INS [15,16]. Despite of the pres-
ence of in vitro data obtained from culture supernatants,
there is no enough information on serum levels of
sIL-12 as far as we are aware of. We found that
serum sIL-12 levels were statistically similar in AS,
RS and the controls. Also, there were no correlation
between sIL-12 and lymphocyte sub-population and
serum IgE levels in our study. According to these
findings, sIL-12 seems to have no role in pathogenesis
of nephrotic syndrome in our patients. Macrophages
and monocytes produce sIL-12 as an early response
to antigenic stimuli; therefore, we think that in vitro
sIL-12 production of lipopolisaccaride stimulated per-
ipheral blood mononuclear cells of INS patients could
not be specific for nephrotic syndrome [17]. Indeed,
GATA-3 (Th2-specific transcription factor) related
Th2 cytokines are shown to negatively influence the
production of sIL-12 in patients with INS [18,19].
Adhesion molecules mediate the initial rolling of in-
flammatory cells along endothelial cells and platelets in
response to pathological process. However, the role of
adhesion molecules in the pathophysiology of nephrotic
syndrome in children is not well known. Unlike other
adhesion molecules, E-selectin is synthesized only by
endothelial cells when activated by interleukin-1 or
tumor necrosis factor- [20,21]. Thus, sE-selectin could
Figure 2 The positive correlations between E-selectin and triglyceride (r = 0.757, p < 0.0001) and cholesterol (r = 0.824, p < 0.0001)
levels in nephrotic patients with active stage.
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in nephrotic syndrome. We found that sE-selectin levels
were increased in patients with AS and it returned to
normal after treatment. To our best knowledge, thesefindings are the first report on sE-selectin in children
with nephrotic syndrome. We think that endothelial in-
jury is not related to Th2 response and B lymphocyte
due to lack of any relationship between sE-selectin and
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These findings also cannot be explained with IL-12
levels which not increased in our patients with AS since
IL-12 is demonstrated to increase the sE-selectin ligands
on T lymphocytes [22]. The possible reason for in-
creased E-selectin level might be the presence of
hyperlipidemia which is reported to enhance the se-
cretion of IL‐6 and TNF-alpha [23]. On the other
hand, hypercholesterolemia has been reported to in-
crease superoxide anion production in endothelial cells
[24]. In fact, we found that cholesterol and triglyceride
levels were positively correlated with E-selectin levels in
our patients. Hyperlipidemia seems to be associated with
endothelial damage.
Glucocorticoids are of proven benefit in the treatment
of proteinuria in patients with SSNS. We found that
sE-selectin levels decreased but high ratios of sCD19
+ CD23+ B cells persisted with steroids therapy in pa-
tients with RS. Present findings suggest that steroid
therapy can improve the endothelial cell functions but
appears to fail to regulate expansion of B-cell in pa-
tients with RS. We think that expansion of the
sCD19 + CD23+ B cells might contribute to the con-
tinuation of immune response in patients with RS.
The implication of B-cells in SSNS remains to be in-
vestigated in detail in future studies.
Conclusions
In summary, present study suggests that patients with
SSNS have abnormalities in their sCD23 + CD19+ B cells
and show endothelial injury with high E-selectin levels.
Furthermore, sIL-12 seems to have no role in pathogen-
esis of SSNS which reflects normal Th1 response.
Present findings also implied that the patients with SSNS
have T regulatory cell defect as indicated by normal
sCD4 + CD25+ T cell ratio despite the increased immune
response including high levels of IgM, IgE, CD19 and
expanded sCD23 + CD19+ B cells.Competing interests
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